Product Description
AE 941 [Arthrovas, Neoretna, Psovascar] is shark cartilage extract that inhibits angiogenesis. AE 941 acts by blocking the two main pathways that contribute to the process of angiogenesis, matrix metalloproteases and the vascular endothelial growth factor signalling pathway. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/15293867/)
Mechanisms of Action: Angiogenesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AEterna Zentaris
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Kidney Cancer|Adenocarcinoma|Renal Cell Carcinoma|Large Cell Carcinoma|Carcinoma, Adenosquamous|Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer
Phase 2: Multiple Myeloma|Plasmacytoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00022282 |
CDR0000068801 | P2 |
Completed |
Multiple Myeloma|Plasmacytoma |
2007-03-01 |
2019-03-21 |
Treatments |
|
NCT00005995 |
CDR0000067999 | P3 |
Completed |
Kidney Cancer|Renal Cell Carcinoma |
2007-03-01 |
2019-03-21 |
||
NCT00005838 |
NCI-2012-02725 | P3 |
Completed |
Non-Small-Cell Lung Cancer|Carcinoma, Adenosquamous|Large Cell Carcinoma|Squamous Cell Carcinoma|Adenocarcinoma |
2007-02-01 |
2020-10-26 |
Primary Endpoints |